Saxagliptin
- Generic Name
- Saxagliptin
- Brand Names
- Kombiglyze, Komboglyze, Onglyza, Qtern, Qternmet
- Drug Type
- Small Molecule
- Chemical Formula
- C18H25N3O2
- CAS Number
- 361442-04-8
- Unique Ingredient Identifier
- 8I7IO46IVQ
- Background
Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.
- Indication
Treatment of type 2 diabetes mellitus to improve glycemic control in combination with other agents or as monotherapy.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Effects of Antidiabetic Medications on the Postprandial State in Prediabetes
- Conditions
- Interventions
- First Posted Date
- 2014-04-04
- Last Posted Date
- 2018-07-03
- Target Recruit Count
- 21
- Registration Number
- NCT02104739
- Locations
- 🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States
DPP-4 Inhibition, Incretins and Islet Function
- Conditions
- Interventions
- First Posted Date
- 2014-03-17
- Last Posted Date
- 2017-08-23
- Lead Sponsor
- Lund University
- Target Recruit Count
- 24
- Registration Number
- NCT02089438
- Locations
- 🇸🇪
Clinical Research Department, Lund, Sweden
Bioequivalence/Food Effect - Saxa/Dapa Dual Fixed Dose Combination (FDC)
- Conditions
- Interventions
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2015-06-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 72
- Registration Number
- NCT02060201
Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients
- First Posted Date
- 2013-12-31
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- George Washington University
- Target Recruit Count
- 42
- Registration Number
- NCT02024477
- Locations
- 🇺🇸
Medical Faculty Associates Inc, Washington, District of Columbia, United States
Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis
- Conditions
- Interventions
- First Posted Date
- 2013-12-27
- Last Posted Date
- 2017-06-28
- Lead Sponsor
- Woman's
- Target Recruit Count
- 38
- Registration Number
- NCT02022007
- Locations
- 🇺🇸
Woman's Hospital, Baton Rouge, Louisiana, United States
Effect of Saxagliptin on Pre-Diabetes Mellitus and Obesity
- Conditions
- Interventions
- First Posted Date
- 2013-10-10
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Shandong Provincial Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT01960205
- Locations
- 🇨🇳
Shandong Provincial Hospital, Jinan, Shandong, China
DPP4inhibitors in Type 1 Diabetes
- First Posted Date
- 2013-08-14
- Last Posted Date
- 2019-10-15
- Lead Sponsor
- University of Dundee
- Target Recruit Count
- 28
- Registration Number
- NCT01922817
- Locations
- 🇬🇧
Clinical research centre, Ninewells Hospital and Medical School, Dundee, United Kingdom
Incretin Effect on the Immunological Phenotype
- First Posted Date
- 2013-02-01
- Last Posted Date
- 2016-10-11
- Lead Sponsor
- Medical University of Graz
- Target Recruit Count
- 15
- Registration Number
- NCT01782261
- Locations
- 🇦🇹
Medical University Graz, Graz, Austria
Metabolomic Variations in the Saxagliptin-Treated Type 2 Diabetes Mellitus Patients
- First Posted Date
- 2013-01-15
- Last Posted Date
- 2016-06-14
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 569
- Registration Number
- NCT01768208
- Locations
- 🇨🇳
Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Mechanistic Assessment of the Properties of Saxagliptin in Subjects Undergoing Coronary Artery Bypass Graft Surgery
- Conditions
- Interventions
- First Posted Date
- 2013-01-10
- Last Posted Date
- 2015-05-29
- Lead Sponsor
- Duke University
- Target Recruit Count
- 12
- Registration Number
- NCT01765270
- Locations
- 🇺🇸
Heart Center Research, LLC, Huntsville, Alabama, United States
🇺🇸Arkansas Cardiology, PA, Little Rock, Arkansas, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.